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Abstract
The cornea is a transparent, avascular tissue that acts as the major refractive surface of the eye. Corneal transparency,
assured by the inner stroma, is vital for this role. Disruption in stromal transparency can occur in some inherited or acquired
diseases. As a consequence, light entering the eye is blocked or distorted, leading to decreased visual acuity. Possible
treatment for restoring transparency could be via viral-based gene therapy. The stroma is particularly amenable to this
strategy due to its immunoprivileged nature and low turnover rate. We assayed the potential of AAV vectors to transduce
keratocytes following intra-stromal injection in vivo in the mouse cornea and ex vivo in human explants. In murine and
human corneas, we transduced the entire stroma using a single injection, preferentially targeted keratocytes and achieved
long-term gene transfer (up to 17 months in vivo in mice). Of the serotypes tested, AAV2/8 was the most promising for gene
transfer in both mouse and man. Furthermore, transgene expression could be transiently increased following aggression to
the cornea.
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Introduction
The cornea is the transparent, avascular tissue at the front of the
eye that covers the iris. As well as acting as a protective barrier to
physical and pathogenic injury, the cornea is the major refractive
surface of the eye [1]. It is primarily composed of three zones: an
external stratified epithelium, a thick collagenous stroma, and a
cuboidal monolayer of epithelial-like cells called endothelium. On
the anterior side, the corneal epithelium consists of 6–7 layers of
cells separated by tight junctions. The epithelium has a
regenerative turnover of 1–2 weeks. On the posterior side, the
endothelium is a non-regenerative monolayer of cells, which forms
a leaky barrier regulating the hydration of the cornea. In the
centre of the cornea is the stroma, which is primarily composed of
an extracellular matrix and makes up 90% of the corneal
thickness. The predominant residing stromal cell type is the
keratocyte, a type of specialised fibroblast, which plays a role in
general repair and maintenance [2].
Disruption of corneal transparency due to disease, infection or
injury, results in the blocking or distortion of light entering the eye
and hence leads to decreased visual acuity. Corneal pathologies
are a significant and underestimated cause of unilateral blindness,
leading to between 1.5 and 2 million new cases each year (http://
www.who.int/blindness/causes/priority/en/index9.html). In the
most severe cases, corneal transplantation is required. However,
despite the fact that the cornea is an immunoprivileged organ,
graft rejection is relatively common and thus local immunosup-
pressive treatments are required for successful grafting. With
regards to the long-term outcome, transplanted cornea have a
relatively limited lifespan, usually due to new injury, low level
chronic rejection or progression of initial illness [3]. In light of
these caveats, accessibility of the cornea renders viral-based gene
therapy a viable alternative in the case of certain inherited and
acquired diseases [4]. The outermost epithelium is the most
accessible, however, paradoxally, gene transfer to this tissue has
proven the most challenging due to its impenetrability and high
turnover [5,6]. In contrast, gene transfer to the innermost
endothelium is feasible following injection of viral vectors into
the anterior chamber [7,8,9,10], with which it is in direct contact.
The corneal stroma plays the most important role in corneal
transparency [1]. This tissue is separated from the corneal
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brane, and from the endothelium by a thin acellular layer,
Descemet’s membrane. Owing to this isolation, previous studies
have shown that administration of viral vectors via the epithelium
or endothelium does not result in efficient transduction of the
stromal keratocytes [1]. Techniques allowing direct access of
vectors to the stroma include topical application following lamellar
keratotomy and laser (or mechanic) ablation of the epithelium.
Although these routes of administration result in stromal
transduction, transgene expression is generally limited to the
anterior surface of the cornea in the vicinity of the lesion
[9,11,12,13,14]. In contrast, in 2004, Carlson et al. reported
efficient and widespread transduction of the stroma following
direct injection [15], thus suggesting the potential of this technique
for clinical application.
In addition to route of administration, another factor for
efficient transduction is the choice of viral vector. Various studies
have addressed delivery into the cornea with retroviral, lentiviral,
herpes simplex and adenovirus vectors, with varying efficiencies
depending on the cells targeted (for review see [1,5]). More
recently, attention has focused on the use of adeno-associated viral
(AAV) vectors for ocular gene therapy, likely due to the proof of
principal of these vectors for the treatment of retinal degeneration
in humans [16,17]. In vivo studies, in preclinical models, have
demonstrated stromal transduction with AAV vectors following
removal of the epithelium, and efficiency depended on the
serotype tested [12,14].
In this study, we targeted the corneal stromal cells by direct
injection. We compared four AAV serotypes for their transduction
efficiency and duration in vivo in the mouse cornea, and ex vivo in
human corneal explants. We found that, in murine and human
corneas, we transduced cells throughout the stroma via a single
injection, preferentially targeted keratocytes, and achieved long-
term gene transfer. Of the four serotypes, AAV2/8 was the most
efficient in mice and humans. Furthermore, transgene expression
could be reactivated when the stroma was damaged.
Results
I. In vivo mouse cornea studies
AAV2/8 transduction is the most efficient. We produced
four AAV vectors harbouring the AAV2 inverted terminal repeats
(ITRs) and capsids from serotypes 1, 2, 5 or 8. Each vector
contained an enhanced green fluorescent protein (EGFP)
transgene under control of a cytomegalovirus (CMV) early
promoter. To compare the onset and duration of expression of
the four serotypes, we administered the same number of vector
genomes (vg; dictated by the maximum volume (2 ml) injectable) of
each vector into the eyes of two mice (i.e. 2 mice per vector) by
intra-stromal injection. EGFP fluorescence was assayed in vivo once
a week for a month using a fluorescence stereomicroscope adapted
for small animal imaging. One-week post-administration, EGFP
fluorescence was detected in the eyes injected with AAV2/1
(Fig. 1a,b) and AAV2/8 (Fig. 1m,n), and epifluorescence
continued to increase over one month (Figs. 1c,d and 1o,p,
respectively). Generally, the EGFP signal was stronger with the
AAV2/8 vector. From 4-wk post-injection, fluorescence was
detected in the mouse eyes injected with AAV2/2 (Figs. 1e–h),
although at a relatively low level. In 3 of 4 eyes, we did not detect
EGFP fluorescence from AAV2/5 (Figs. 1i–l); in 1 eye a transient
signal appeared at week 2 that disappeared by week 3.
Taken together, our results suggested that AAV2/8 was the
most efficient serotype for transducing the murine corneal stroma.
AAV2/8 transduction continues at least 17 mo in
vivo. Following intra-stromal injection, EGFP expression from
AAV2/8 was apparent at 3-d post-injection (Fig. 2a). Transgene
expression was localised to the corneal epithelium by histological
studies (Fig. 2b). This relatively short-lived signal was likely due to
vector leaking into the epithelium because of the needle’s
trajectory. From 7-d post-injection, a signal in a different focal
plane became apparent by in vivo microscopy. These latter EGFP+
cells were clearly visible by day 35 (Fig. 2c) and were located in the
stroma by histological studies (Fig. 2d). At 6-mo post-injection, the
EGFP-expressing cells could still be seen (Fig. 2e) throughout the
stroma (Fig. 2f) and fluorescence continued to be detected up to
17-mo post-injection, the longest time point studied (Figs. 2g–j).
These results demonstrated that transgene expression from the
AAV2/8 vector was long-lived ($17 mo) in the corneal stroma.
However, although a dose-dependent effect was observed (higher
doses resulted in stronger, and more rapid onset of, expression),
the initial number of EGFP-expressing cells was lower than that
obtained with other vectors, notably adenoviruses ([15] and our
data with human adenovirus serotype 5 (Ad5; Figure S1a–d) and
canine adenovirus serotype 2 (CAV-2; Figure S1e–h)).
AAV2/8 transduces mouse keratocytes. In mice and
humans, keratocytes have characteristic interconnecting dendritic
processes and constitute the major (96%) cell type of the cornea
[2]. The number and morphology of the EGFP-expressing cells
observed under the microscope was consistent with keratocytes.
There exist a number of established markers that can be used to
identify human keratocytes, whereas this is not the case for the
mouse cells. A widely used marker for human keratocytes is CD34
[18]. By contrast, in the mouse stroma, CD34 was reported as a
marker of hemopoietic stem cells that have a rounded shape and
represent ,2.5% of the stromal population [19]. In the absence of
a commercially available mouse keratocyte antibody, we
incubated sections with an anti-CD34 antibody. In the control
stroma (Figs. 3a–d), the CD34+ cell population represented
approximately 100% of the stromal cells, which was reminiscent
of keratocytes. Consistently, the morphology of the CD34+ cells
was elongated rather than rounded. In the AAV2/8-transduced
cornea (Figs. 3e–h), the number of CD34+ cells was reduced to
17.8362.3% (compare Fig. 3e with 3a). This decrease in the
proportion of CD34+ cells appeared to be due to either cell
proliferation or migration as suggested by the increased number of
cell nuclei following injection (compare Fig. 3g with 3c). We
detected 4.160.8% of EGFP+ cells in the transduced stroma and
observed a co-localisation of the CD34 and EGFP signals (Fig. 3h).
The remaining 1.5% of the mouse stromal cells was reported to
be macrophages [19,20]. Therefore, we incubated 10-mm thick
sections from control and AAV2/8-transduced mouse corneas
with an antibody against the macrophage marker F4/80. In the
control stroma (Figs. 3i–l), 18.864.9% of the cells were F4/80+.I n
the AAV2/8-transduced cornea (Figs. 3m–p), we detected
7.862% of F4/80+ cells (compare Fig. 3m with 3i) and an
augmentation in the number of cell nuclei (compare Fig. 3o with
3k). Nonetheless, we did not observe co-localisation between the
F4/80 and EGFP signals (Fig. 3h).
Taken together, we concluded that the AAV2/8 vector did not
transduce resident stromal macrophages. Based on morphology
and number, the transduced cells were consistent with keratocytes.
Although we cannot formally rule out transduction of CD34+
hemopoetic stem cells, the number and shape of these cells were
incompatible with this population.
AAV2/8 transgene expression can be hyper-activated in
vivo. In contrast to most internal organs, the cornea is
continuously exposed to environmental aggressions and
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etiologic agents for external ocular infection [21,22]. To evaluate
the effect of transient aggression subsequent to AAV delivery, we
injected the AAV2/8-transduced mouse cornea with a first
generation human Ad5 vector expressing beta-galactosidase
(Adbgal; [23]), with lipopolysaccharide (LPS), or with PBS 1-wk
post-AAV administration, and recorded EGFP levels 24 h later
(adenovirus vectors and LPS, but not PBS, are known
inflammatory agents). As mentioned above, at 1-wk post-AAV2/
8 administration, we began to see EGFP expression in the corneal
stroma (Figs. 4a,b). When we re-injected the corneas with Adbgal,
LPS or PBS at this time-point and assayed in vivo fluorescence 24 h
later, we detected a significant hyper-activation in EGFP
expression throughout the corneal stroma (Figs. 4c,d). The
expression was not detectable 1 wk later (data not shown). To
exclude an aggravation due to phosphate ions, as PBS was present
in all three conditions, we performed a second injection with
saline, which increased the number of EGFP+ cells to the same
extent (data not shown). Notably, EGFP expression was boosted in
the corneal stroma regardless of AAV serotype, but the intensity of
the boost was serotype-dependent: AAV2/8 (Figs. 4c,d).AAV2/1
(Figs. 4e,f).AAV2/2 (Figs. 4g,h).AAV2/5 (Figs. 4i,j).
Furthermore, EGFP expression from AAV2/8 could be
reactivated by PBS injection up to 94 days (latest time point
tested) after the initial AAV2/8 injection (Fig. 4k). We also tested
whether we could repeatedly reactivate EGFP expression by
reinjecting the same eye a second time with PBS (on day 117 post-
AAV2/8 injection). EGFP expression was reactivated but less
extensively (Fig. 4l).
To identify the EGFP-expressing cells following PBS injection,
we incubated sections of a PBS-injected mouse eye with an anti-
CD34 antibody. We clearly identified 3368.5% of CD34+ cells in
the stroma; counting was difficult due to the faint red signal
coupled to the elongated shape of the cells and, as a consequence,
the percentage of CD34+ cells was likely underestimated. We
observed 57.865.7% of EGFP+ cells, and the EGFP signal co-
localised with the CD34 signal (Figs. 5a–d). Following incubation
with an anti-F4/80 antibody, we detected 8.460.7% of F4/80+
cells. By contrast, we did not observe a co-localisation of the F4/80
and EGFP signals (Figs. 5e–h). These observations indicate that
the CD34+/F4/802 population showing hyper-activated EGFP
expression is the same cell population as that initially transduced
by AAV2/8 administration.
Figure 1. Transduction efficiency of AAV vectors in the mouse cornea. EGFP expression (indicated by arrows) in the mouse cornea detected
by in vivo epifluorescence microscopy 1-wk post-injection of AAV2/1 (a), AAV2/2 (e), AAV2/5 (i) and AAV2/8 (m) vectors. (b, f, j, n) Higher
magnification of a, e, i and m, respectively. (c, g, k, o) EGFP expression in the same corneas detected 4-wk post-injection. (d, h, l, p) Higher
magnification of c, g, k and o, respectively. Magnifications a, e, g, i, k, m, o:2 0 6; b:4 3 6; c:2 5 6, d:5 3 6; f, j:3 5 6; h:4 4 6, l:3 3 6; n:4 0 6; p:4 5 6. For
reference, the diameter of an adult mouse eye is ,3.5 mm. The large green spot in centre of photos is the pupil of the mouse eye. The asterisk in
panels i to l indicates an opaque lesion on the mouse eye that was present from the beginning of the experiments.
doi:10.1371/journal.pone.0035318.g001
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cornea caused a transient boost in EGFP expression. Furthermore,
the intensity of the boost was relative to the initial efficiency of
transduction of the serotype used. This trend suggested that the
fold increase per serotype was similar. The commonality with each
vector is of course the AAV2 genome, which suggests that a
cellular response to aggression can induce transcription from the
ITRs and/or the CMV promoter.
AAV2/8 vector genomes decrease while mRNA levels
increase after corneal re-injection. To determine whether
the rapid decline in EGFP expression following a second corneal
injection was due to the loss of vector genomes or a return to the
previous level of transcription, we followed the fate of AAV2/8
DNA (Figs. 6a,b,c) and mRNA (Figs. 6d,e,f) using Real-Time
PCR. We found that vector genome levels were relatively stable
both 8- and 14-d post-AAV2/8 injection (Fig. 6c). In contrast,
following injection with PBS at day 7 post-AAV2/8 injection, we
detected a 1.9-fold decrease at day 8, and a 4-fold decrease at day
14.
An analysis of EGFP mRNA levels showed that levels were at
background on days 8 and 14 post-AAV2/8 administration in the
absence of a second injection of PBS (Fig. 6f). In contrast, PBS
injection on day 7 resulted in a 65-fold increase in EGFP mRNA
levels on day 8, which returned to background levels by day 14.
This kinetics of mRNA levels was consistent with that of EGFP
expression observed by fluorescent microscopy.
Taken together, these results indicated that a second injection in
the cornea caused a partial loss in vector genomes concomitant
with a transient increase in mRNA levels. The subsequent
reduction of EGFP expression appeared to be due to the return
to basal levels of vector mRNA.
II. Ex vivo human cornea studies
AAV2/8 efficiently transduces human corneas and
preferentially targets keratocytes. To be clinically relevant,
we evaluated AAV vector transduction efficiency in human
corneal explants. We injected each vector into the stroma and
EGFP expression was followed weekly by in vivo fluorescence
microscopy. One-week post-injection, fluorescence could be
detected in the human corneas injected with AAV2/1 (Fig. 7a,b)
and AAV2/8 (Fig. 7i,j), although expression was higher with the
AAV2/8 vector. From 3-wk post-injection, fluorescence was
detected in the corneas injected with AAV2/2 (Figs. 7e,f),
although at a relatively low level. Over the duration of the
experiment, we did not detect a significant signal following
injection with AAV2/5 (data not shown). For the AAV2/1, 2/2
and 2/8 vectors, expression persisted for ,8 wk (endpoint of
experiment), however, the qualitative and quantitative expression
profiles varied: AAV2/8-transduced cells expressed high levels of
GFP, and their size (80–200 mm; [24]) and shape was consistent
with keratocytes (Figs. 7k,l). By contrast, the EGFP-expressing cells
transduced with the AAV2/1 (Figs. 7c,d) or 2/2 (Figs. 7g,h)
vectors were smaller, less abundant, and did not display a
characteristic dendritic form.
As mentioned above, CD34 is a marker for quiescent human
keratocytes [18,25]. Once keratocytes become activated and
differentiate into myofibroblasts, they stop expressing CD34 and
begin expressing alpha-smooth muscle actin (a-SMA; [26]).
Consequently, we incubated 10-mm-thick sections from AAV2/
8-transduced human corneas with antibodies against these
markers. Co-localisation of the EGFP signal with anti-CD34
(Figs. 8a–d) and anti- a-SMA (Figs. 8e–h) labelling indicated that
the transduced cells were both quiescent and activated keratocytes.
Figure 2. Onset and duration of AAV2/8 transgene expression. (a) Fluorescence detected by in vivo microscopy 3-d post-injection of AAV2/8.
(b) At this time-point, EGFP expression (arrow) was in the corneal epithelium (asterisk) as determined by histological epifluorescence studies. EGFP
(arrows) could be detected in the stroma by 1-mo post-injection by in vivo (c) and histological (d) studies. EGFP expression continued throughout the
mouse cornea at 6-mo post-injection in vivo (e) and by histological studies (f; montage of two overlapping photographs). EGFP expression persisted
at 17-mo post-injection (longest time-point tested) as seen by in vivo (g) and histological studies (h). (i, j) Processing and analysis of the stack
acquisition of the 10-mm-thick section shown in panel h using the Imaris software. Magnifications a, c, e and g:2 0 6.
doi:10.1371/journal.pone.0035318.g002
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efficiency of the AAV vectors was similar between the mouse and
human corneas, and that AAV2/8 was the most efficient serotype
for transducing the corneal keratocytes of both species.
Discussion
The eye is highly amenable to gene therapy because it is i)
accessible, ii) small and enclosed allowing the use of low vector
doses, and iii) sequestrated from the general circulation rendering
it immune-privileged. The retina has received the most attention
in recent years culminating in the successful clinical trials in 2008
for Leber’s congenital amaurosis, a hereditary congenital blindness
due to a breakdown of the visual cycle [16,17]. An AAV2/2 vector
was used to deliver the missing gene into the retinal pigment
epithelium allowing an amelioration/restoration of sight in visually
impaired subjects. Thus, at least for now, AAV vectors appear to
be safe and efficient for the eye.
Although the field is less advanced, there is a growing interest in
using gene therapy to target the cornea. Potential applications are
the correction of corneal neovascularisation [10,27] or scarring
[28,29], as well as the treatment of certain genetic diseases [4].
Among these, the multisystemic lysosomal storage diseases (LSDs)
are particularly appealing candidates as the associated corneal
symptoms are not alleviated by systemic treatment in contrast to
other organs [30]. Corneal anomalies in LSDs often include
corneal clouding (as in the case of mucopolysaccaridosis (MPS)
type VI and VII; [4]) or photophobia (as in the case of cystinosis;
[31,32]) and are due to abnormal storage in the stromal
keratocytes.
A highly efficient way to transduce stromal keratocytes is to
administer vectors via intra-stromal injection. This technique
causes a transient separation of the stromal matrix allowing the
injected liquid to be distributed throughout. In this way, we
achieved widespread transduction of the stroma, in contrast to
topical administration following lamellar keratotomy [9,11] or
laser ablation [12,13] of the epithelium, which result in local
transduction. Furthermore, as the stroma is delineated by
Bowman’s and Descemet’s membranes, vector dissemination and
transduction of the epithelium or endothelium appeared negligi-
ble. Within 24 h following injection, the cornea returned to its pre-
injected transparent state, likely due to the removal of the injected
Figure 3. Cell specificity of AAV2/8 transduction. (a–d) Anti-CD34 staining (in red) of a non-injected mouse cornea shows abundant CD34+
cells. (e–h) Anti-CD34 labelling (in red) of a mouse cornea 24 h post-injection with 3610
9 vg of AAV2/8. Intra-stromal injection results in a decrease in
the proportion of CD34+ cells (in red) due to an augmentation in the number of cell nuclei (in blue). The EGFP signal co-localises (arrows and
arrowheads) with the CD34-labelled cells. Inset in h shows a higher magnification of the cells indicated by arrowheads minus the Hoechst filter. (i–l)
Anti-F4/80 staining (in red) of a non-injected mouse cornea showing a low number of F4/80+ cells. (m–p) Anti-F4/80 labelling (in red) of a mouse
cornea 24 h post-injection with 3610
9 vg of AAV2/8. The EGFP signal does not co-localise (arrows) with the F4/80-labelled cells.
doi:10.1371/journal.pone.0035318.g003
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endothelial cells. Underlying this transformation is also the highly
efficient and unique repair mechanism intrinsic to the cornea [33],
which rapidly restores transparency. However, this repair
mechanism also represents a challenge for achieving long-term
gene expression. For example, in 2004, Carlson et al. demonstrated
the potential of intra-stromal injection by administrating a human
adenovirus vector containing a transgene under control of the
keratocan promoter [15]. Consistent with our observations with
adenovirus vectors, transduction was throughout the cornea, but
peaked at 24 h and then declined significantly by 1 wk. Although
the corneal keratocytes are quiescent cells, and thus an ideal
population for non-integrative vectors, they have the particularity
of losing their quiescence and differentiating into activated
myofibroblasts during corneal repair. In terms of timing,
keratocytes immediately adjacent to the lesion begin to undergo
cell death within a few hours after injury creating an acellular zone
[33]. Six hours post-injury, keratocytes neighbouring this zone
begin to lose their quiescence, become activated, divide, and
within 24 h migrate towards the damaged area. Repopulation
begins from around 48 h. This cell death and division process is
consistent with clearance of the transduced cells and loss of the
episomal vector genomes, respectively.
By contrast, we found that, in general, transgene expression
from AAV vectors was detected from 1 wk post-injection (earlier
at higher doses) and increased during the following weeks, likely
due to the lag time required for their single stranded genome to
convert to double-stranded. Moreover, transgene expression was
still detectable at 17-mo post-administration. AAV, like Ad,
vectors are theoretically ‘‘non-integrating’’ and should follow the
same fate after corneal repair. It is possible that i) AAV vectors
integrate into stromal keratocytes [34], ii) the episomal vector
genomes form long concatamers that are not lost during cell
division [35], or iii) some of the vector genomes remain
encapsidated in the cell [36] and retain infectivity [37], thus
potentially entering neighbouring cells. Along this line, intact AAV
Figure 4. EGFP expression levels following PBS injection in the transduced mouse cornea. EGFP expression 7-d post-AAV2/8 injection by
in vivo (a) and histological (b) studies. (c, d) Increase in EGFP expression 24 h after PBS injection of the AAV2/8-transduced cornea. Panels b and d are
composed of two overlapping photographs. (e) Increase in EGFP expression from AAV2/1 (cf. Fig. 1c) following a second injection of PBS. (f)
Histological section showing the localisation of EGFP expression from AAV2/1 to the corneal stroma. g) Smaller increase in EGFP expression from
AAV2/2 (cf. Fig. 1g) following PBS injection. (h) Histological section showing the localisation of EGFP expression from AAV2/2 to the corneal stroma. (i)
Barely detectable EGFP expression (arrows) from AAV2/5 (cf. Fig. 1k) following PBS injection. (j) Histological section showing the localisation of EGFP
expression (arrowheads) from AAV2/5 to the corneal stroma. (k) Hyper-activation of EGFP expression in a mouse eye that was injected with PBS 94 d
post-AAV2/8 injection. (l) Less extensive activation of EGFP expression in the mouse eye shown in panel k following a second PBS injection 117 d
post-AAV2/8 injection. Magnifications a, c, l:2 6 6; e, g, i, k:2 2 6.
doi:10.1371/journal.pone.0035318.g004
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transfer and, interestingly, these particles were found in cells that
did not express the transgene [36]. Regardless, a certain number
of AAV-carrying cells are inevitably eliminated during the initial
corneal repair mechanism. Thus, we hypothesise that the relatively
lower numbers of transgene-expressing cells following AAV-
transduction (versus Ad-transduction) likely stems from the smaller
percentage of AAV-carrying cells that persist following repair
(Fig. 9a).
Eyes are the targets of many environmental and pathological
stimuli. Thus, we explored possible adverse effects associated with
a transient aggression. In 2002, Tsai et al. reported that transient
ocular anterior segment inflammation provoked transgene expres-
sion in endothelial cells following injection of an AAV2/2 vector
expressing beta-galactosidase from a CMV promoter into the
anterior chamber of rabbits [38]. Inflammation was induced by
LPS treatment whereas there was no effect following PBS
injection. In our study, the intra-stromal administration of LPS
(or Ad5) following AAV2 vector injection also provoked transgene
expression. This suggested that a larger number of cells harboured
AAV genomes than was initially suspected based on transgene
expression, but that these were either still encapsidated or
transcriptionally inactive. In contrast to the report by Tsai et al.,
a PBS (or saline) injection also provoked transgene expression in
our study. This suggests that in the case of intra-stromal
administration, it is the lesion rather than the substance that
causes the inflammation. More specifically, disruption of the
basement epithelial membrane may result in the production of
cytokines from the epithelium that induce the repair process: IL-
1a initiates cell death in the underlying stroma and TGFb
transforms adjacent keratocytes into activated myofibroblasts (for
review see [2]; Fig. 9b). We attempted to prevent inflammation by
applying anti-inflammatory drugs (dexamethasone, sulfasalazine)
prior to PBS injection, but the results were inconclusive.
Tsai et al. also reported that induced AAV-transgene expression
in the endothelium gradually diminished as the inflammation
subsided (by 50% 5-d post-injection and to background levels 15-d
post-injection when inflammation was no longer detectable) [38].
In the case of the corneal stroma, transgene expression diminished
more rapidly and was undetectable 1-wk post-injection. This is
reminiscent of the timing of clearance following direct adenovirus
administration [15]. Our Real-Time PCR data showed that the
loss of transgene expression coincided with a decrease in vector
genomes and a loss of mRNA. Consistent with the report by Tsai et
al., we also reactivated transgene expression with a subsequent (i.e.
third) injection, albeit at lower levels. This transcriptional
upregulation confirms that AAV genomes remained following
the second wave of corneal repair (Fig. 9c), as suggested by the
Real-Time PCR results at 14-d post-PBS injection. Based on our
data, we cannot determine whether the reactivated transgene
expression is due to de novo uncoating of encapsidated virions or
reactivation of transcriptionally-silenced genomes.
De novo uncoating would be in harmony with the report by
Johnson and Samulski showing that a population of AAV2 virions
enter the nucleus following cell entry and accumulate in the
nucleolus [37]. These virions may then use nucleolar disruption
during mitosis, genotoxic stress or coinfection, as a trigger to
release their genetic contents. Once released, the genome would
need to undergo second strand synthesis, which is reportedly
facilitated by DNA repair [39]. Inflammation leads to DNA
damage of the host cell genome and results in active production of
DNA repair enzyme and cofactor [38]. This would account for the
immediately high level of transgene expression we observed
following injection and disruption of the basement epithelial
membrane (Fig. 9b). Furthermore, as non-disrupted virions
released from the nucleolus retain infectivity [37], a proportion
of them may be released and infect neighbouring cells following
division of the mother cell. This could contribute to the lower level
of transgene expression observed following another round of
inflammation.
Intra-stromal injection is a viable technique for specifically
transducing keratocytes throughout the corneal stroma. Moreover,
AAV vectors are capable of long-term gene expression, although,
the number of transduced cells that remain following injection and
repair may not be sufficient to administer adequate amounts of a
therapeutic protein in view of treating genetic diseases. The
exception may be the case of some LSDs. For example, for LSDs
due to a defective lysosomal enzyme such as in MPS VI or VII, the
phenomena of cross-correction, whereby the lysosomal enzymes
escape from cells and are taken up by neighbouring cells [40],
requires gene transfer only to a subset of cells. Therefore, it is
possible that AAV transduction could result in phenotypic
correction. Alternatively, in the case of a non-secreted protein,
such as a membrane transporter as is the case for cystinosis [41],
Figure 5. EGFP-expressing cell population following PBS injection in the transduced mouse cornea. (a–d) Anti-CD34 staining (in red) of
a mouse cornea 24 h post-PBS injection (same eye shown in Fig. 4C). The CD34 signal co-localises with the EGFP signal (arrows and arrowheads). (e–f)
Anti-F4/80 staining (in red) of a mouse cornea 24 h post-PBS injection. The F4/80 signal does not co-localise with the EGFP signal (arrows).
doi:10.1371/journal.pone.0035318.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35318Figure 6. Real-Time PCR analysis of vector genome (a,b,c) and mRNA (d,e,f) levels following AAV2/8 transduction of mouse cornea.
Amplification curves of (a) GAPDH and (b) EGFP in DNA extracted from injected mouse eyes. To aid visualisation, only one of the duplicate curves is
shown. (c) Graphical representation of the concentration of EGFP normalised to that of GAPDH in each sample (the colour of the curves in a and b
matches those of the corresponding bars in c). As a control, EGFP DNA could not be detected following injection and re-injection of the mouse
cornea with PBS (PBS PBS). In contrast, EGFP DNA levels were detected and relatively stable both 8- and 14-d post-AAV2/8 transduction (blue bars).
Following a second injection of PBS 7-d post-transduction, a 1.9- and 4-fold decrease in EGFP DNA was detected on days 8 and 14, respectively (red
bars). Amplification curves of (d) GAPDH and (e) EGFP in RNA extracted from injected mouse eyes. (f) Graphical representation of the concentration
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transduced keratocytes is insufficient to achieve correction via
transgene expression. By contrast, Galiacy et al. recently addressed
the potential of AAV gene therapy for treating or preventing
corneal scarring, which can lead to corneal blindness. A single
intra-stromal injection of an AAV2/8 vector encoding a fibril
collagenase (MMP14), reduced the expression levels of major
genes involved in scarring, suggesting a potential for therapeutic
applications [29].
Is it possible to overcome/exploit the corneal repair mechanism
to retain transduced cells and maintain activated transcription?
One possibility would be to target keratocyte precursors residing in
the stroma rather than keratocytes themselves. A resident
population of stem cells has been identified in the adult human
stroma [42]. These cells differentiate into keratocytes and restore
transparency upon injection into the scarred corneas of mice [43].
Thus, if one could stably transduce this population in vivo, they
could repopulate the cornea following repair. Along this line, the
normal mouse cornea may contain two populations of bone
marrow-derived leukocytes (totalling 4% of stromal cells), both of
which are distinct from stromal keratocytes (96%): the larger
population (,2.5%) resembles CD34+ hemopoetic stem cells,
whereas the smaller population (,1.5%) are macrophages [19].
We observed transgene expression in CD34+ cells but not in F4/
80+ cells. Therefore, if the transduced CD34+ cells do represent a
stem cell population, it is tempting to speculate that these cells
could repopulate the cornea following injury and differentiate into
keratocytes.
Interestingly, the profile and efficiency of transduction of the
different AAV serotypes in the cornea was consistent between
mouse and man. Moreover, the transduced human cells were bona
fide keratocytes. To our knowledge, this is the first study showing
the transduction of human corneal explants by intra-stromal
injection. Two previous reports detailed the transduction of
human explants by incubation in a culture medium containing
AAV vectors [12,14]. In contrast to these studies, our approach
results in widespread transduction of the stromal keratoyctes that
was highest with AAV2/8, followed by AAV2/1 and that was low
to negligible with AAV2/2 or 2/5. Therefore, of the serotypes we
tested, we identify AAV2/8 as the most potentially interesting for
keratocyte transduction in the human cornea by intra-stromal
injection.
Materials and Methods
Production of recombinant AAV vectors
AAV2 vectors harbouring the capsids from serotypes 1, 2, 5 and
8, and expressing EGFP, were produced by the Centre for Animal
of EGFP normalised to that of GAPDH in each sample (the colour of the curves in d and e matches those of the corresponding bars in f). As a control,
EGFP RNA levels could not be detected following injection and re-injection of the mouse cornea with PBS. Similarly, EGFP RNA levels could not be
detected 8- and 14-d post AAV2/8 transduction. In contrast, a second injection of PBS 7-d post-transduction resulted in a 65-fold increase in EGFP
RNA levels on day 8 (red bar). RNA levels were no longer detectable by day 14.
doi:10.1371/journal.pone.0035318.g006
Figure 7. Transduction efficiency of the AAV vectors in the human corneal explants. One-wk post-injection, using in vivo microscopy,
EGFP expression can be seen in throughout the cornea following intra-stromal injection of the vectors AAV2/1 (a) and AAV2/8 (i). (b, j) Higher
magnification of the boxed regions in a and i, respectively. (e) Three-weeks post transduction, EGFP expression can be detected following AAV2/2
injection. (f) Higher magnification of the boxed area in e.( c, g, k) EGFP expression on histological sections of each cornea 8-wk post-injection of
AAV2/1, 2/2, 2/8, respectively. (d, h, l) Imaris-treated images of c, g, k, respectively, showing EGFP-expressing cells.
doi:10.1371/journal.pone.0035318.g007
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35318Figure 8. Intra-stromal injection of AAV2/8 in the human cornea results in transduction of keratocytes. (a–d) Anti-CD34 labelling (in
red) of a human cornea co-localises with EGFP-expressing cells (in green) and identifies these cells as quiescent keratocytes. (e–h) Anti-a–SMA
labelling (in red) of a human cornea co-localises with EGFP-expressing cells (in green) and identifies these cells as activated keratocytes.
doi:10.1371/journal.pone.0035318.g008
Figure 9. Schematic representation of the events following PBS injection and hyper-activation of EGFP expression. (a) Following
initial AAV2/8 injection, a large number of cells harbour viral particles or vector genomes but a small number of cells express EGFP (in green). (b)
Twenty-four h post-PBS injection, the disruption of the epithelial basement membrane results in the release of cytokines that induce the repair
process. This process involves cell death in the stroma immediately underlying the injection site, which reduces the vector genome levels (,2-fold
decrease), and cell migration from the limbal region. The ensuing events also result in either de novo uncoating of encapsidated virions or
reactivation of transcriptionally-silenced genomes leading to activated EGFP expression (consistent with the 65-fold increase in EGFP mRNA levels).
(c) One-week post-PBS injection, the cornea has returned to its basal state and is no longer expressing EGFP (low mRNA levels). The cell death process
has removed a number of transduced keratocytes (4-fold decrease in vector genome levels). However, cells harbouring the virions are still present
(persisting DNA levels) as a subsequent PBS injection still can activate EGFP expression but less extensively.
doi:10.1371/journal.pone.0035318.g009
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Autonoma de Barcelona (Spain). The AAV-helper plasmids
containing Rep2 and Cap for each serotype were kindly provided
by JM Wilson, University of Pennsylvania, Philadelphia, PA, USA.
Viral supernatants were concentrated on iodixanol gradients. The
titres were: AAV2/1 – 5.3610
11 vg/ml; AAV2/2 – 1.9610
12 vg/
ml; AAV2/5 – 8.8610
11 vg/ml; AAV2/8 – 1.56610
12 vg/ml.
Ethics statement
All animal breeding and experiments were carried out in
accordance with the European and National guidelines for the
care and use of laboratory animals (Council Directive 86/6009/
EEC). Institutional and regional ethics committees (‘‘Comite ´
d’e ´thique de la Languedoc Roussillon’’; permit number CE LR
0709) reviewed and approved the work on animals. Post-mortem
human corneal explants were collected by the Centre for Human
Biological Collections of Montpellier (CCBH-M; CHRU Mon-
tpellier, France). Corneas that did not fulfil the endothelial density
inclusion criteria for transplantation were provided for research
purposes in accordance with French regulations by the tissue bank
at the St Eloi hospital (CHRU Montpellier).
In vivo transduction
C57BL/6 mice were maintained in a controlled environment
with a 12 h/12 h light/dark cycle, housed in groups of 10
maximum and allowed food and water ad libitum. Prior to
injection, animals were anaesthetised by an intraperitoneal
injection of 10 mg/kg xylazine (Bayer Pharma, Puteaux, France)
and 100 mg/kg ketamine (Merial, Lyon, France). Intra-stromal
injection was performed by first creating a small incision in the
corneal epithelium using the tip of a 26-gauge needle. The incision
was performed equidistance between the corneo-scleral junction
and the corneal centre. A 33-gauge needle attached to a 10 ml
Hamilton microliter syringe (Sigma-Aldrich, St. Quentin Fallavier,
France) was then introduced through the incision into the corneal
stroma and 10
9 vg of vector in 2 ml of PBS were injected (unless
otherwise stated). For the secondary injections, 1-wk post-vector
administration (unless otherwise stated), the previously-injected
mouse cornea was reinjected with 2 mlo fa) 10
9 physical particles
of Adbgal, b) 2 ng/ml LPS Escherichia coli 0127:B8 (Sigma Aldrich),
c) PBS without Ca
2+ and Mg
2+ (Invitrogen, Cergy Pontoise,
France) or d) saline (0.9% NaCl solution), and fluorescence
observed 24 h and 1 wk later.
Corneal explants and ex vivo transduction
Corneal explants were cultured in CorneaMax media (Eurobio,
Courtaboeuf, France) at 31uC in sealed bottles. Intra-stromal
injection was performed by inserting a 29-gauge needle attached
to a 0.5 ml syringe through the endothelium into the stroma to
administer a total of 5610
10 vg of AAV in 300 ml PBS.
In vivo and ex vivo microscopy studies
Mice were anaesthetised using 2% isoflurane in an induction
chamber with an 02 flow rate of 0.2 L/min prior to observation.
Fluorescence in the mouse eye and in the human corneal explants
was observed using an M2Bio fluorescence (dissecting) stereomi-
croscope assembled by Kramer Scientific (Amesbury, MA, USA)
on a Zeiss Stemi V6 stereomicroscope platform (Nanterre,
France), and equipped with a CCD camera (Small Animal
Imaging Platform (IPAM), Montpellier, France). Image acquisition
was performed using the MetaMorph imaging program (Molec-
ular devices, Wokingham, Berkshire, United Kingdom).
Histological studies
Following sacrifice, mouse eyes were enucleated, fixed in 4%
paraformaldehyde/PBS for 24 h, placed in 20% sucrose/PBS for
24 h, and embedded in OCT matrix (CellPath, Newton, Powys,
UK). The same protocol was used for the human corneal explants.
For the visualisation of EGFP fluorescence, the nuclei of 10-mm-
thick sections were labelled with 0.2 mg/ml bisBenzimide Hoechst
(Sigma-Aldrich) for 5 min prior to mounting in DakoCytomation
fluorescent mounting media (Dako, Trappes, France). For the
immunofluorescence studies, sections were blocked in 10% horse
serum/2% BSA. Primary antibodies were incubated on sections
for 1 h, and the secondary antibody incubated 45 min, at room
temperature prior to Hoescht labelling and mounting. For the
mouse sections, the primary antibodies used were 1:300 dilution
rat anti-mouse F4/80 (Clone BM8; Caltag laboratories, Invitro-
gen) and 1:100 rat anti-mouse CD34 (Ebiosciences, Clinisciences,
Montrouge, France) and the secondary antibody was 1:1000
dilution chicken anti-rat IgG-Alexa Fluor 555 (Molecular probes,
Invitrogen). For the human sections, the primary antibodies used
were 1:100 mouse anti-human CD34 (clone B1-3C5; Abcam,
Cambridge, UK) and 1:50 mouse anti-human a-SMA (Clone 1A4;
R&D Systems, Lille, France) and the secondary antibody 1:500
goat anti-mouse IgG-Alexa Fluor 546 (Molecular probes, Invitro-
gen). Sections were observed using a Zeiss LSM 510 META
confocal microscope and image acquisition performed using
MetaMorph. For a clear interpretation, certain images were
further processed and analysed using the Imaris software (Bitplane
Scientific Software, Zurich, Switzerland). Immunolabelled cells
were quantified manually and the results expressed as the mean 6
standard error of the mean (n=3 to 11).
Real-Time PCR amplification
Five groups, each comprising 6 mice, were used. Group 1 (PBS
PBS): Day 0 – PBS injected in one eye; day 7 - the injected eye was
reinjected with 2 ml PBS; day 8 - the mice were sacrificed. Group
2 (AAV2/8 8 d): Day 0 – AAV2/8 injected in one eye; day 8 - the
mice were sacrificed. Group 3 (AAV2/8 14 d): Day 0 – AAV2/8
injected in one eye; day 14 - the mice were sacrificed. Group 4
(AAV2/8 8 d PBS): Day 0 – AAV2/8 injected in one eye; day 7 -
the transduced eye was injected with 2 ml PBS; day 8 - the mice
were sacrificed. Group 5 (AAV2/8 14 d PBS): Day 0 – AAV2/8
injected in one eye; day 7 - the transduced eye was injected with
2 ml PBS; day 14 - the mice were sacrificed. Fluorescence was
checked in vivo on day 8 (groups 1, 2 and 4) and on day 14 (groups
3 and 5). The transduced cornea of each mouse was divided in
two, one half for DNA-, and the other for RNA-, extraction. The
cornea was homogenised and DNA extracted by proteinase K
digestion and phenol-chloroform extraction as previously de-
scribed [44]. RNA was extracted individually from each cornea as
described [45] and then, due to insufficient quantities, the RNA
within each experimental group was pooled for cDNA synthesis.
cDNA was synthesised from 1 mg total RNA using the Superscript
III reverse transcriptase according to the manufacturer’s instruc-
tions (Invitrogen, Cergy Pontoise, France). Genomic DNA and
cDNAs were amplified by Real-Time PCR using a SYBR green
mix [46] and a LightCycler apparatus (Roche Molecular
Biochemicals) as described [47] The primers for the reaction
were as follows: EGFP F: 59 CAG AAG AAC GGC ATC AAG
GT 39; EGFP R: 59 CTG GGT GCT CAG GTA GTG G 39;
GAPDH F: ACA GTC CAT GCC ATC ACT GCC 39;
GAPDH R: 59 GCC TGC TTC ACC ACC TTC TTG 39.
EGFP and GAPDH concentrations were calculated using
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expressing EGFP concentration as a function of the GAPDH
concentration per sample. Samples were assayed in duplicate.
Supporting Information
Figure S1 Transduction of Ad5 and CAV-2 vectors in the
mouse cornea. (a) Fluorescence detected by in vivo microscopy
1-d post-intra-stromal injection of 10
9 pp of an Ad5 vector
expressing EGFP. (b–d) EGFP expression is localised to the
corneal stroma as determined by histological studies. (e)
Fluorescence detected by in vivo microscopy 1-d post-injection of
10
9 pp of a CAV-2 vector expressing EGFP. (f–h) Histological
studies localise EGFP expression to the corneal stroma. Magni-
fications a and e:2 5 6.
(TIF)
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